The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
796
July 14, 1989
View Complete Issue         Table of Contents 2019 
Octreotide - A Synthetic Somatostatin
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Octreotide - A Synthetic Somatostatin
July 14, 1989 (Issue: 796)
Octreotide acetate (Sandostatin - Sandoz), a synthetic octapeptide that mimics the actions of somatostatin, was recently approved by the US Food and Drug Administration for symptomatic treatment of patients with metastatic carcinoid or VIPomas ...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Octreotide - A Synthetic Somatostatin
Article code: 796b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.